GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.

GSK Announces FDA Acceptance of New Meningococcal Jab BLA

GSK has delivered encouraging updates from ongoing trials of its vaccines for Shingles and Gonorrhoea. In the follow-up Zoster trial for the now on-sale Shingrix vaccine, efficacy was more than 80% for patients over 50 between 6-11 years after the jab with no new safety issues identified.

GSK encouraged by Shingles and Gonorrhoea trials

British drugmaker GSK said on Wednesday long-term data showed that its blockbuster shingles vaccine, Shingrix, had 79.7% efficacy in participants aged 50 years and above, six to 11 years after vaccination.

GSK says efficacy of its shingles vaccine remains high after years

GSK (GSK) closed at $40.80 in the latest trading session, marking a +0.27% move from the prior day.

GSK (GSK) Rises But Trails Market: What Investors Should Know

GSK (GSK) concluded the recent trading session at $41.19, signifying a +0.81% move from its prior day's close.

GSK (GSK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

GSK is in good shape even with the overhang of the Zantac litigation according to analysts at Berenberg. Clear messaging on long-term targets and delivery in the interim is helping to build a more constructive dialogue with investors, says the broker.

GSK at a compelling valuation, suggests broker

GSK (GSK) concluded the recent trading session at $41.79, signifying a -1.49% move from its prior day's close.

GSK (GSK) Registers a Bigger Fall Than the Market: Important Facts to Note

Recently, Zacks.com users have been paying close attention to Glaxo (GSK). This makes it worthwhile to examine what the stock has in store.

GSK PLC Sponsored ADR (GSK) is Attracting Investor Attention: Here is What You Should Know

GSK (GSK) closed at $42.99 in the latest trading session, marking a +0.47% move from the prior day.

Here's Why GSK (GSK) Gained But Lagged the Market Today

Bio-Techne

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Techne (TECH). But which of these two stocks is more attractive to value investors?

GSK or TECH: Which Is the Better Value Stock Right Now?

GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.

GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US

Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces it has regained full ownership from GSK of HTL0027477 (formerly GSK4381406), a clinic-ready, highly selective, first-in-class, oral GPR35 agonist in development as a potential new treatment for Inflammatory Bowel Diseases (IBD).

Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

British pharmaceutical giant GSK said on Wednesday it will cap out-of-pocket costs at $35 per month for all its inhaled asthma and chronic lung disease medicines for eligible patients in the United States, following similar moves by two of its rivals.

GSK to cap out-of-pocket inhaler costs in US

Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.

GSK Outperforms Industry on Strength in Key Drugs & Vaccines

In the most recent trading session, GSK (GSK) closed at $42.32, indicating a +0.43% shift from the previous trading day.

GSK (GSK) Increases Yet Falls Behind Market: What Investors Need to Know

Jemperli, a cancer drug manufactured by GlaxoSmithKline, improved survival for patients diagnosed with a form of uterine cancer by more than one year, the British drugmaker said Saturday, the latest findings of a late-stage trial by GSK seeking to expand the use of the treatment.

Jemperli Cancer Drug: What To Know As GSK Says It Improves Survival For Uterine Cancer Patients

LOS ANGELES--(BUSINESS WIRE)-- #AIDS--AIDS Healthcare Foundation (AHF) is calling on the government of Trinidad and Tobago to consider issuing a compulsory license for Tivicay (dolutegravir), a GSK antiretroviral (ARV) drug that treats HIV, which currently costs 25 times more than available biosimilar generics in neighboring Caribbean countries. In February, AHF and the Medical Research Foundation of Trinidad & Tobago sent a letter to GSK CEO Dame Emma Walmsley, which in part stated, “We urge you t.

AHF Urges Trinidad and Tobago to Sidestep Greedy GSK

Glaxo (GSK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

GSK PLC Sponsored ADR (GSK) Is a Trending Stock: Facts to Know Before Betting on It

Booz Allen Hamilton Hld

Molson Coors Brewing

Toyota Motor

Tyson Foods

We have narrowed our search to five low-beta stocks with a solid dividend yield. These are: TAP, TSN, TM, GSK and BAH.

Inflation Remains Sticky in February: 5 Safe Picks

Here is how GSK (GSK) and Capricor Therapeutics (CAPR) have performed compared to their sector so far this year.

Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?

GSK plc (NYSE:GSK ) TD Cowen 44th Annual Health Care Conference March 4, 2024 2:50 PM ET Company Participants Luke Miels - CCO Conference Call Participants Stephen Scala - TD Cowen Stephen Scala Well, good afternoon, and welcome once again. We're delighted to have GSK here at the 44th Annual Cowen Health Care Conference.

GSK plc (GSK) TD Cowen 44th Annual Health Care Conference (Transcript)

Ambev

AstraZeneca

Alibaba

Baidu

British American Tobacco

Anheuser-Busch InBev

Imperial Brands PLC

JD.com

Kao Corp

Kone Oyj

Medtronic

Nestle SA

Omron Corp

Pernod Ricard SA

Reckitt Benckiser Group PLC

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

International Wide-Moat Stocks On Sale - The March 2024 Heat Map

GSK PLC (LSE:GSK, NYSE:GSK) cancer discovery Blenrep's blockbuster potential has been 'reawakened', according to Shore Capital. The broker was commenting after Thursday's phase III results, which showed the drug performed significantly better than the standard of care in patients with a hard-to-treat blood-borne cancer called multiple myeloma.

GSK: Has Blenrep's blockbuster status been restored?

PHILADELPHIA--(BUSINESS WIRE)--GSK doubles COiMMUNITY grant funding, launches patient resources, as adult vaccination rates begin to show promising rise.

GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise

GSK said on Thursday a study showed its experimental drug Blenrep helped extend survival in patients with a type of blood cancer without symptoms worsening, marking a potential comeback for the drug after several setbacks.

GSK's blood cancer drug meets main goal in late-stage trial; analysts tout comeback

News for GlaxoSmithKline Stock (GSK)